Jeremy R. Delman
Counsel
Corporate
Jeremy R.
Delman
Jeremy R.
Delman
Counsel
Corporate
Jeremy represents public and private companies in connection with a variety of strategic transactions, including mergers and acquisitions, divestitures, spin-offs, joint ventures, investments and venture capital financings, with a particular emphasis on the technology, financial services and life sciences industries. Jeremy also counsels companies on corporate governance matters, including related to shareholder activism and takeover defense.
Prior to joining Fenwick, Jeremy led the M&A and Corporate Ventures legal group at Assurant (NYSE: AIZ), where he was responsible for the company’s global acquisitions, dispositions and minority investments. Jeremy began his legal career in the M&A group of a New York-based law firm.
During law school, Jeremy was a member of the Columbia Business Law Review and was a Harlan Fiske Stone Scholar.
- Analog Devices in its acquisition of Linear Technology
- Assurant in its acquisition of HYLA Mobile
- Cisco in its acquisition of Accedian Networks
- Emergent BioSolutions in its spin-off of Aptevo Therapeutics
- Emerson in its acquisition of Fluxa
- Fakespot in its sale to Mozilla
- Graybug Vision in its reverse merger with CalciMedica
- Molekule in its merger of equals with AeroClean Technologies
- Neoleukin Therapeutics in its reverse merger with Neurogene
- Pardes Biosciences in its sale to Foresite Capital
- PTC Therapeutics in its acquisition of certain assets of Marathon Pharmaceuticals
- Regal Entertainment Group in its sale to Cineworld
- Shockwave Medical in its acquisition of Neovasc
- Skyworks Solutions in its proposed acquisition of PMC-Sierra
- Staples in its sale to Sycamore Partners
- TMX Group in its acquisition of Trayport from Intercontinental Exchange
* Includes experience from a previous firm
- Analog Devices in its acquisition of Linear Technology
- Assurant in its acquisition of HYLA Mobile
- Cisco in its acquisition of Accedian Networks
- Emergent BioSolutions in its spin-off of Aptevo Therapeutics
- Emerson in its acquisition of Fluxa
- Fakespot in its sale to Mozilla
- Graybug Vision in its reverse merger with CalciMedica
- Molekule in its merger of equals with AeroClean Technologies
- Neoleukin Therapeutics in its reverse merger with Neurogene
- Pardes Biosciences in its sale to Foresite Capital
- PTC Therapeutics in its acquisition of certain assets of Marathon Pharmaceuticals
- Regal Entertainment Group in its sale to Cineworld
- Shockwave Medical in its acquisition of Neovasc
- Skyworks Solutions in its proposed acquisition of PMC-Sierra
- Staples in its sale to Sycamore Partners
- TMX Group in its acquisition of Trayport from Intercontinental Exchange
* Includes experience from a previous firm
- Amazon
- Cisco
- Emerson Electric
- Figma
- GeneDx
- Melinta Therapeutics
- Neoleukin Therapeutics
- Pardes Biosciences
- Pattern Energy Group
- Shockwave Medical
- Urbint
- Amazon
- Cisco
- Emerson Electric
- Figma
- GeneDx
- Melinta Therapeutics
- Neoleukin Therapeutics
- Pardes Biosciences
- Pattern Energy Group
- Shockwave Medical
- Urbint
New York City Bar Association Committee on Mergers, Acquisitions & Corporate Control Contests
New York City Bar Association Committee on Mergers, Acquisitions & Corporate Control Contests